Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice

Nephrology

Volumn 15, Issue 3, 2010, Pages 327-335

  Higashi, Keishi ^a   Oda, Takashi ^a   Kushiyama, Taketoshi ^a   Hyodo, Toshitake ^a   Yamada, Muneharu ^a   Suzuki, Shigenobu ^a   Sakurai, Yutaka ^a   Miura, Soichiro ^a   Kumagai, Hiroo ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II type 1 receptor blockers; Fibrosis; Peroxisome proliferator activated receptor ; Plasminogen activator inhibitor 1; Ureteral obstruction

Indexed keywords

ADIPONECTIN; CANDESARTAN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; URETER OBSTRUCTION; URINARY EXCRETION;

ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BIOLOGICAL MARKERS; CHEMOKINE CCL2; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBROSIS; KIDNEY; KIDNEY DISEASES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TETRAZOLES; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA; URETERAL OBSTRUCTION;

EID: 77950477513     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01253.x     Document Type: Article

References (28)

1. Meguid El Nahas A, Bello AK. Chronic kidney disease: The global challenge. Lancet 2005 365 : 331 340.
2. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998 352 : 1252 1256.
3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001 345 : 861 869.
4. Hebert LA. Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006 354 : 189 191.
5. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: Evidence and mechanisms of action. J. Am. Soc. Nephrol. 2006 17 : 2999 3012.
6. Oda T, Jung YO, Kim HS et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 2001 60 : 587 596.
7. Omasu F, Oda T, Yamada M et al. Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats. Am. J. Physiol. Renal. Physiol. 2007 293 : F1292 8.
8. Nakamura T, Yamamoto E, Kataoka K et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008 51 : 296 301.
9. Namikoshi T, Tomita N, Satoh M et al. Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. Hypertens. Res. 2008 31 : 745 755.
10. Sarafidis PA, Lasaridis AN, Nilsson PM et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am. J. Hypertens. 2005 18 : 227 234.
11. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001 59 : 1899 1910.
12. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int. 2006 70 : 1223 1233.
13. Westerweel PE, den Ouden K, Nguyen TQ, Goldschmeding R, Joles JA, Verhaar MC. Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing. Am. J. Physiol. Renal. Physiol. 2008 294 : F379 84.
14. Kawai T, Masaki T, Doi S et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab. Invest. 2009 89 : 47 58.
15. Efrati S, Berman S, Chachashvili A et al. Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction. Nephrology (Carlton). 2009 14 : 189 197.
16. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J. Am. Soc. Nephrol. 2006 17 : 2974 2984.
17. Nicholas SB, Aguiniga E, Ren Y et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005 67 : 1297 1307.
18. Collins SJ, Alexander SL, Lopez-Guisa JM et al. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron. Exp. Nephrol. 2006 104 : e23 34.
19. Ma LJ, Nakamura S, Aldigier JC et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J. Am. Soc. Nephrol. 2005 16 : 966 976.
20. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int. 2000 58 : 2425 2436.
21. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000 58 : 251 259.
22. Oda T, Hotta O, Taguma Y et al. Clinicopathological significance of intratubular giant macrophages in progressive glomerulonephritis. Kidney Int. 1998 53 : 1190 1200.
23. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J. Clin. Invest. 2008 118 : 3522 3530.
24. Hilgers KF, Hartner A, Porst M, Veelken R, Mann JF. Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: Relation to kidney inflammation. Circulation 2001 104 : 1436 1440.
25. Ohga S, Shikata K, Yozai K et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. Renal. Physiol. 2007 292 : F1141 50.
26. Ohashi K, Iwatani H, Kihara S et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2007 27 : 1910 1917.
27. Fujita K, Maeda N, Sonoda M et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol. 2008 28 : 863 870.
28. Kamada Y, Matsumoto H, Tamura S et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. 2007 47 : 556 564.